Found: 29
Select item for more details and to access through your institution.
Integrated slice-specific dynamic shimming for whole-body diffusion-weighted MR imaging at 1.5 T.
- Published in:
- MAGMA: Magnetic Resonance Materials in Physics, Biology & Medicine, 2021, v. 34, n. 4, p. 513, doi. 10.1007/s10334-020-00898-6
- By:
- Publication type:
- Article
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 4, p. e33, doi. 10.1111/bjh.17903
- By:
- Publication type:
- Article
The management of Castleman disease.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 3, p. 328, doi. 10.1111/bjh.17688
- By:
- Publication type:
- Article
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 4, p. 750, doi. 10.1111/bjh.17377
- By:
- Publication type:
- Article
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. e19, doi. 10.1111/bjh.17391
- By:
- Publication type:
- Article
COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 1, p. e14, doi. 10.1111/bjh.17168
- By:
- Publication type:
- Article
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 2, p. e83, doi. 10.1111/bjh.16874
- By:
- Publication type:
- Article
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial).
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 573, doi. 10.1111/bjh.15551
- By:
- Publication type:
- Article
Is the revised International staging system for myeloma valid in a real world population?
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 3, p. 451, doi. 10.1111/bjh.14341
- By:
- Publication type:
- Article
Guidelines for the use of imaging in the management of patients with myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 3, p. 380, doi. 10.1111/bjh.14827
- By:
- Publication type:
- Article
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 6, p. 908, doi. 10.1111/bjh.14547
- By:
- Publication type:
- Article
Time to redefine Myeloma.
- Published in:
- 2015
- By:
- Publication type:
- Editorial
Bone Marrow Assessment in Asymptomatic IgM Monoclonal Gammopathies - Reply to Varettoni et al.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 2, p. 302, doi. 10.1111/bjh.13095
- By:
- Publication type:
- Article
Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 3, p. 316, doi. 10.1111/bjh.12760
- By:
- Publication type:
- Article
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
- Published in:
- European Journal of Haematology, 2013, v. 90, n. 5, p. 420, doi. 10.1111/ejh.12070
- By:
- Publication type:
- Article
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid<sup>TM</sup> (CC-4047) and their relationship with venous thrombosis.
- Published in:
- European Journal of Haematology, 2005, v. 74, n. 4, p. 293, doi. 10.1111/j.1600-0609.2004.00393.x
- By:
- Publication type:
- Article
Risk of relapse of multiple myeloma following kidney transplantation.
- Published in:
- Clinical Kidney Journal, 2019, v. 12, n. 2, p. 216, doi. 10.1093/ckj/sfy137
- By:
- Publication type:
- Article
OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S2, doi. 10.1016/S2152-2650(21)02077-2
- By:
- Publication type:
- Article
Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving ≥VGPR following PAD induction in the Phase 2 PADIMAC study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e288, doi. 10.1016/j.clml.2019.09.475
- By:
- Publication type:
- Article
Comparing clinical trial data against a real world dataset – progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e283, doi. 10.1016/j.clml.2019.09.467
- By:
- Publication type:
- Article
Added Value of Contrast-Enhanced T1-Weighted and Diffusion-Weighted Sequences for Characterization of Incidental Findings on Whole Body Magnetic Resonance Imaging in Plasma-Cell Disorders.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e145, doi. 10.1016/j.clml.2017.03.261
- By:
- Publication type:
- Article
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 6, p. 1, doi. 10.1038/s41408-021-00507-2
- By:
- Publication type:
- Article
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 323, doi. 10.1002/hon.3102
- By:
- Publication type:
- Article
Re-transplantation after bortezomib-based therapy.
- Published in:
- British Journal of Haematology, 2011, v. 153, n. 5, p. 666, doi. 10.1111/j.1365-2141.2010.08521.x
- By:
- Publication type:
- Article
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
- Published in:
- British Journal of Haematology, 2008, v. 141, n. 1, p. 41, doi. 10.1111/j.1365-2141.2008.07013.x
- By:
- Publication type:
- Article
The Association between Metabolic Syndrome and Multiple Myeloma.
- Published in:
- Acta Haematologica, 2021, v. 144, n. 1, p. 24, doi. 10.1159/000505992
- By:
- Publication type:
- Article
Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 8, p. 2558, doi. 10.1007/s00259-020-05182-2
- By:
- Publication type:
- Article
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
- Published in:
- Oncology & Therapy, 2021, v. 9, n. 1, p. 139, doi. 10.1007/s40487-020-00137-x
- By:
- Publication type:
- Article